Deciphera pharmaceuticals Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Deciphera pharmaceuticals Contact Number

Deciphera Pharmaceuticals Crunchbase Company Profile

5 hours ago Crunchbase.com Show details

(781) 209-6400Legal Name Deciphera Pharmaceuticals, Inc. Stock Symbol NASDAQ:DCPH. Company Type For Profit. Contact Email [email protected]deciphera.com. Phone Number (781) 209-6400. Deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases.

Founded: 2003

Category: Contact NumberShow more

Deciphera Pharmaceuticals (Germany) GmbH Company …

4 hours ago Dnb.com Show details

Company Description: Deciphera Pharmaceuticals (Germany) GmbH is located in München, Bayern, Germany and is part of the Drugs and Druggists' Sundries Merchant Wholesalers Industry. Deciphera Pharmaceuticals (Germany) GmbH has 5 total employees across all of its locations and generates $1.32 million in sales (USD).

Category: Contact NumberShow more

DECIPHERA PHARMACEUTICALS (ITALY) SRL Company …

1 hours ago Dnb.com Show details

Find company research, competitor information, contact details & financial data for DECIPHERA PHARMACEUTICALS (ITALY) SRL of MILANO, MILANO. Get the latest business insights from Dun & Bradstreet.

Category: Contact NumberShow more

Contact IR Deciphera Pharmaceuticals, Inc.

1 hours ago Investors.deciphera.com Show details

212-600-1902Investor Relations Contact: Argot Partners Investor Relations Maghan Meyers 212-600-1902 deciphera@argotpartners.com

Category: Contact SupportShow more

Deciphera Pharmaceuticals, LLC in Olympia, WA Company

3 hours ago Bizapedia.com Show details

(877) 858-3855Deciphera Pharmaceuticals, LLC is a Washington Foreign Limited-Liability Company filed On October 7, 2019. The company's filing status is listed as Active and its File Number is 604526355. The Registered Agent on file for this company is C T Corporation System and is located at 711 Capitol Way S Ste 204, Olympia, WA 98501.

Email Address: [email protected]
Founded: Oct 07, 2019
Phone Number: (877) 858-3855
Location: 200 Smith Street, Waltham, 02451, MA

Category: Contact NumberShow more

Deciphera Pharmaceuticals Vendor Privacy Notice

5 hours ago Deciphera.com Show details

why Deciphera Pharmaceuticals, number, email address, work address , resume or curriculum vitae ; If you would like to exercise any of these rights, please contact Deciphera or Deciphera’s EU Representative for the GDPR listed above. You may also have the right to lodge a complaint with

Category: Contact NumberShow more

Deciphera Pharmaceuticals LinkedIn

8 hours ago Linkedin.com Show details

Deciphera Pharmaceuticals 17,721 followers on LinkedIn. Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to …

Category: Contact NumberShow more

Deciphera Pharmaceuticals Announces Restructuring to

7 hours ago Investors.deciphera.com Show details

WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 30, 2021-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced a corporate restructuring intended to prioritize clinical development of select programs, …

Category: Contact NumberShow more

Deciphera Pharmaceuticals Announces Restructuring to

6 hours ago Finance.yahoo.com Show details

WALTHAM, Mass., November 30, 2021--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with

Category: Contact NumberShow more

Deciphera AccessPoint™ Enrollment Form

2 hours ago Decipheraaccesspoint.com Show details

I authorize Deciphera Pharmaceuticals and its affiliates, business partners, vendors, and other agents (collectively, “business partners” and together with Deciphera Pharmaceuticals, “Deciphera”) to provide me with services for which I am eligible under the Program.

Category: Contact NumberShow more

Deciphera Pharmaceuticals: The 75% Haircut Doesn’t Seem

1 hours ago Seekingalpha.com Show details

Summary. Deciphera Pharmaceuticals is the unusual case of a commercial-stage company whose drug succeeds at first but then has a major setback. Top-line data from a key phase 3 trial suggest that

Category: Contact NumberShow more

Here is What Hedge Funds Think About Deciphera

5 hours ago Insidermonkey.com Show details

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) was in 29 hedge funds’ portfolios at the end of September.The all time high for this statistic is 36. DCPH has seen an increase in support from the

Category: Contact NumberShow more

EIN 200299725 Deciphera Pharmaceuticals, Inc., Waltham

3 hours ago Eintaxid.com Show details

Deciphera Pharmaceuticals, Inc. is a corporation in Waltham, Massachusetts. The employer identification number (EIN) for Deciphera Pharmaceuticals, Inc. is 200299725. EIN for organizations is sometimes also referred to as taxpayer identification number or TIN or simply IRS Number. It is one of the corporates which submit 10-K filings with the SEC.

Category: Contact NumberShow more

Dosing and Administration QINLOCK® (ripretinib)

8 hours ago Qinlockhcp.com Show details

Deciphera takes privacy seriously. By providing your name, email, and address above you are giving Deciphera permission to contact you for marketing and educational purposes. We will not sell or transfer your name, email, or other contact information to any third party for their own marketing use. *

Category: Contact NumberShow more

Deciphera Pharmaceuticals Number of Employees 20162021

2 hours ago Macrotrends.net Show details

Deciphera Pharmaceuticals number of employees from 2016 to 2021. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on addressing key mechanisms

Category: Contact NumberShow more

Privacy Notice for Health Care deciphera.com

7 hours ago Deciphera.com Show details

Deciphera Pharmaceuticals, LLC and its affiliates ("Deciphera" or "we"), each a Data Controller, is committed to protecting your privacy and will make all reasonable efforts to protect your personal data business contact information, such as your business postal address, telephone, mobile and fax number, e-mail address;

Category: Contact NumberShow more

Deciphera Pharmaceuticals Is Trying to Beat Financial

1 hours ago Investorplace.com Show details

Deciphera Pharmaceuticals (NASDAQ: DCPH) is a biotech company that develops drugs mainly for the treatment of cancer.Right now, DCPH stock shares are down nearly 85% year-to-date (YTD), at $7.70

Category: Contact NumberShow more

Priya Jain Sr. Director, Head of Pharmacovigilance

4 hours ago Apollo.io Show details

View Priya Jain's business profile as Sr. Director, Head of Pharmacovigilance at Deciphera Pharmaceuticals. Find Priya's email address, mobile number, work history, and more.

Category: Contact NumberShow more

Deciphera Pharmaceuticals Provides Corporate Update and

4 hours ago Streetinsider.com Show details

Deciphera will webcast its corporate presentation from the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 9:00 AM ET. A live webcast of the presentation can be

Category: Contact NumberShow more

Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) Has Great

7 hours ago Stocksregister.com Show details

According to the data, the short interest in Deciphera Pharmaceuticals Inc. (DCPH) stood at 4.43% of shares outstanding as of Sep 14, 2021; the number of short shares registered in Aug 12, 2021 reached 2.84 million. The stock has fallen by -83.83% since the beginning of the year, thereby showing the potential of a further growth.

Category: Contact NumberShow more

Deciphera Announces Positive CHMP Opinion for QINLOCK® for

7 hours ago Finance.yahoo.com Show details

WALTHAM, Mass., September 17, 2021--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with

Category: Contact NumberShow more

Deciphera Pharmaceuticals, Inc. (DCPH) 10K Annual Reports

6 hours ago Last10k.com Show details

Inside Deciphera Pharmaceuticals, Inc.'s 10-K Annual Report: Financial - Income Highlight Interest and Other Income, Net For the year ended December 31, 2020 compared to the same period in 2019, the decrease in interest and other income, net, was primarily due to decreases in interest income earned on our cash equivalents and marketable …

Category: Contact NumberShow more

Deciphera Pharmaceuticals (DCPH) Announces Approval of

1 hours ago Streetinsider.com Show details

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that the

Category: Contact NumberShow more

Deciphera Announces Approval of QINLOCK® in the United

3 hours ago Benzinga.com Show details

Deciphera Pharmaceuticals, Inc. statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important

Category: Contact NumberShow more

Deciphera Pharmaceuticals Provides Corporate Update and

9 hours ago Biospace.com Show details

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals LLC (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today provided a corporate update and highlighted key 2022 milestones in conjunction with its presentation at the 40 th Annual J.P. …

Category: Contact NumberShow more

What 6 Analyst Ratings Have To Say About Deciphera

5 hours ago Markets.businessinsider.com Show details

According to 6 analyst offering 12-month price targets in the last 3 months, Deciphera Pharmaceuticals has an average price target of $22.0 with a high of $64.00 and a low of $10.00. Below is a

Category: Contact NumberShow more

Deciphera Pharmaceuticals Announces TopLine Results from

Just Now Businesswire.com Show details

Deciphera Press Release: FDA Grants Full Approval of Deciphera Pharmaceuticals’ QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor [online] May 15, 2020.

Category: Contact NumberShow more

Patient Access and Support QINLOCK® (ripretinib)

2 hours ago Qinlockhcp.com Show details

Deciphera takes privacy seriously. By providing your name, email, and address above you are giving Deciphera permission to contact you for marketing and educational purposes. We will not sell or transfer your name, email, or other contact information to any third party for their own marketing use. *

Category: Support NumberShow more

Deciphera Pharmaceuticals Funding, Financials, Valuation

4 hours ago Crunchbase.com Show details

Deciphera Pharmaceuticals has raised a total of $714M in funding over 5 rounds. Their latest funding was raised on Aug 13, 2019 from a Post-IPO Equity round. Deciphera Pharmaceuticals is registered under the ticker NASDAQ:DCPH . Their …

Category: Contact NumberShow more

Deciphera Pharma Announces Corporate Restructuring; To Cut

1 hours ago Nasdaq.com Show details

(RTTNews) - Biopharmaceutical company Deciphera Pharmaceuticals, Inc. (DCPH) announced Tuesday a corporate restructuring intended to prioritize clinical development of select programs, streamline

Category: Contact NumberShow more

After Phase 3 failure busts blockbuster bid, Deciphera

6 hours ago Medcitynews.com Show details

Deciphera Pharmaceuticals’ corporate restructuring will slash headcount by 35% and stop work on two drug programs. Going forward, the biotech said it will focus on developing drugs that have the

Category: Contact NumberShow more

Current Report Filing (8k)

7 hours ago Ih.advfn.com Show details

DCPH Deciphera Pharmaceuticals Inc Current Report Filing (8-k) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Category: Contact NumberShow more

DECIPHERA PHARMACEUTICALS (UK) LIMITED overview Find and

5 hours ago Find-and-update.company-information.service.gov.uk Show details

People. for DECIPHERA PHARMACEUTICALS (UK) LIMITED (12593299) More. for DECIPHERA PHARMACEUTICALS (UK) LIMITED (12593299) Registered office address. 11th Floor Whitefriars Lewins Mead, Bristol, United Kingdom, …

Category: Contact NumberShow more

Statement of Ownership (sc 13g)

1 hours ago Ih.advfn.com Show details

percent of class represented by amount in row 9 9.81% 12. type of reporting person ia cusip no: 24344t101 13g page 4 of 7 pages item 1. (a) name of issuer deciphera pharmaceuticals inc (b) address of issuer`s principal executive offices 500 totten pond road 6th floor waltham ma 02451 united states item 2.

Category: Contact NumberShow more

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Expected to

1 hours ago Marketbeat.com Show details

Equities analysts expect that Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) will post $23.44 million in sales for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for Deciphera Pharmaceuticals' earnings. The lowest sales estimate is $19.46 million and t

Category: Contact NumberShow more

Deciphera Announces Approval of QINLOCK® in the United

7 hours ago Apnews.com Show details

212-600-1902CONTACT: Investor Relations: Maghan Meyers. Argot Partners. Deciphera@argotpartners.com +1 212-600-1902Media: David Rosen. Argot Partners. [email protected] +1 212-600-1902. KEYWORD: MASSACHUSETTS EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA INDUSTRY KEYWORD: …

Category: Contact NumberShow more

zlabex1017_1525.htm

7 hours ago Sec.gov Show details

This License Agreement (this “Agreement”) is made as of June 10th, 2019 (the “Effective Date”), by and between Deciphera Pharmaceuticals, LLC a limited liability company organized and existing under the laws of Delaware, U.S.A., located at 500 Totten Pond Rd, Waltham, MA 02451, U.S.A., (“Deciphera”), and Zai Lab (Shanghai) Co., Ltd

Category: Contact NumberShow more

Premarket Mover: Deciphera Pharmaceuticals Inc (DCPH) Down

2 hours ago Investorsobserver.com Show details

Deciphera Pharmaceuticals Inc has a Long-Term Technical rank of 0. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 100% of the market scoring higher. In the Biotechnology industry which is number 141 by this metric, DCPH ranks better than 0% of stocks.

Category: Contact NumberShow more

Deciphera Announces Approval of QINLOCK® in the United

8 hours ago Biospace.com Show details

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals LLC, (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing …

Category: Contact NumberShow more

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Receives

7 hours ago Marketbeat.com Show details

Deciphera Pharmaceuticals had a negative net margin of 300.00% and a negative return on equity of 58.56%. During the same period in the previous year, the firm posted ($1.13) EPS. On average, equities analysts forecast that Deciphera Pharmaceuticals will post -5.14 earnings per share for the current year. About Deciphera Pharmaceuticals

Category: Contact NumberShow more

DEF 14A SEC

5 hours ago Sec.gov Show details

each equity incentive award (i.e. options and SARs) of Deciphera Pharmaceuticals, LLC exercisable for common shares were exchanged for an option to purchase the same number of shares of common stock of Deciphera Pharmaceuticals, Inc. multiplied by 5.65, with a corresponding adjustment to divide the exercise price by 5.65.

Category: Contact NumberShow more

Deciphera Pharmaceuticals Provides Corporate Update and

9 hours ago Marketscreener.com Show details

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today provided a corporate update and highlighted key 2022 milestones in conjunction with its presentation at the 40 th Annual J.P. Morgan Healthcare Conference. The Company …

Category: Contact NumberShow more

5 Pharmaceutical Stocks to Buy Under $20 According to

6 hours ago Insidermonkey.com Show details

2. Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Redmile Group Stake Value: $136,991,000 Percentage of Redmile Group’s 13F Portfolio: 2.38% Number of Hedge Fund Holders: 29

Category: Contact NumberShow more

Flynn James E ownership in DCPH / Deciphera

2 hours ago Fintel.io Show details

021-11-10Flynn James E ownership in DCPH / Deciphera Pharmaceuticals Inc. 2021-11-10 - Flynn James E has filed an SC 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 4,203,900 shares of Deciphera Pharmaceuticals Inc (US:DCPH). This represents 7.19 percent ownership of the company.

Category: Contact NumberShow more

DCPH Deciphera Pharmaceuticals Stock Price Barchart.com

3 hours ago Barchart.com Show details

DCPH : 33.39 (-3.11%) Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 4, 2020 Business Wire - Wed Jul 29, 2020. Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that it will report its second quarter 2020 financial results on Tuesday, August 4, …

Category: Contact NumberShow more

Jpmorgan Chase & Co ownership in DCPH / Deciphera

4 hours ago Fintel.io Show details

02-10 sec.gov - SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Deciphera Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 24344T101 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the …

Category: Contact NumberShow more

Unlocking Growth Opportunity In Deciphera Pharmaceuticals

2 hours ago Stocksregister.com Show details

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) price on Thursday, December 09, fall -0.69% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $8.58. A look at the stock’s price movement, the close in the last trading session was $8.64, moving within a r

Category: Contact NumberShow more

Deciphera Pharmaceuticals Announces Closing of Public

3 hours ago Svhealthinvestors.com Show details

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 19, 2020-- Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the closing of its previously announced registered underwritten public offering. 3,181,818 shares of the Company’s common stock at a …

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Popular Brands

Daikin
Denso
Demant
Dsv
Dlf
Dbs
Dsm
Dana